NCT00679367 · OUTCOME

Number of Participants Removed From Study Due to Toxicities

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis · Source last updated 2017-02-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Number of study participants removed from study treatment due to toxicities

Analysis population: All patients who have had at least one dose of drug.

Melphalan Lenalidomide Dexamethasone dexamethasone: 40 mg once weekly lenalidomide: 10 mg/day days 1-21 melphalan: 5 mg/m2 days 1-4

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Melphalan Revlimid and Dexamethasone	16

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Melphalan Revlimid and Dexamethasone	6	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Number of study participants removed from study treatment due to toxicities

groups

param Type

COUNT_OF_PARTICIPANTS

population Description

All patients who have had at least one dose of drug.

reporting Status

POSTED

time Frame

One year

title

Number of Participants Removed From Study Due to Toxicities

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice